TET2 and leukemia: Treatment with Ruxolitinib did not significantly change the clinical history of the patient we described and did not prevent progression to leukemia, in agreement with the data from Ortmann et al.7, which demonstrated that “TET2-first patients” are less sensitive to Ruxolitinib.